Biotechnology

BioCryst Pharma

BioCryst Pharma released FY2026 Q1 earnings on May 6 During-Market (EST), actual revenue USD 156.41 M (forecast USD 151.12 M), actual EPS USD -2.98 (forecast USD 0.052)

BioCryst Pharma to Release FY2026 Q1 Earnings on May 6 During-Market EST, Forecast Revenue USD 151.12 M, EPS USD 0.052

BioCryst Pharma released FY2025 Q4 earnings on February 26 Pre-Market (EST), actual revenue USD 406.56 M (forecast USD 151.32 M), actual EPS USD 1.1265 (forecast USD 0.0485)

BioCryst Pharma released FY2025 earnings on February 26 Pre-Market EST, actual revenue USD 874.84 M (forecast USD 620.2 M), actual EPS USD 1.21 (forecast USD 0.14)

BioCryst Pharma to release FY2025 Q4 earnings on February 26, Pre-Market EST, with forecast revenue of USD 151.32 M and EPS of USD 0.0485

Astria Therapeutics Inc. Secures $400 Million in Loans for Merger with BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics for $700 Million

BioCryst Pharmaceuticals Reports 2025 Revenue at $601 Million, Forecasting Growth for 2026

BioCryst Pharmaceuticals Receives FDA Approval for Orladeyo Granules

BioCryst's Chief Legal Officer Disposed of Company Common Stock

Wedbush Analyst Maintains Buy Rating on BioCryst with $21 Price Target

BioCryst Pharmaceuticals Plans to Merge with Astria Therapeutics

BioCryst Pharmaceuticals to Acquire Astria Therapeutics for $8.55 per Share and 0.59 Shares

HC Wainwright Raises BioCryst Pharmaceuticals' EPS Forecast for FY2025

BioCryst Pharmaceuticals Releases ORLADEYO® Clinical Trial Data

Belanger Maintains BioCryst's Stock Rating

BioCryst Pharma released FY2025 Q3 earnings on November 3 Pre-Market EST, actual revenue USD 159.4 M (forecast USD 162.97 M), actual EPS USD 0.06 (forecast USD 0.0528)

BioCryst Pharma released FY2025 9 Months earnings on November 3 Pre-Market (EST), actual revenue USD 468.28 M, actual EPS USD 0.0801

Ku Analyst Reiterates Buy Rating on BioCryst Stock

BioCryst Pharma to Release FY2025 Q3 Earnings on November 3, Pre-Market EST; Forecast Revenue USD 162.97 M, EPS USD 0.0528

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

BCRX

QNRX

SBIO

LABU

The Netherton syndrome market is projected to grow from 2026 to 2036, driven by new therapies like QRX003, BCX17725, and ATR-12. The U.S. is expected to lead in market size, with an increase in diagnosed cases due to better diagnostics. Current treatments are mainly symptomatic, highlighting the need for effective, targeted therapies. The development of these new drugs presents significant opportunities in addressing the unmet medical needs of Netherton syndrome patients.

prnewswire

Quoin Pharmaceuticals

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

VG Health

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Azitra

QUOIN PHARMACEUTICALS LTD SPON ADS EACH REP 1 ORD SHS

06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight

BioCryst Pharmaceuticals, Inc. unveiled that the compensation committee of their board of directors provided six newly recruited employees with restricted stock units (RSUs) encompassing a total of 61,750 shares of BioCryst common stock. These RSUs were granted on May 1, 2026, to entice the employees joining the company. The grant aligns with Nasdaq Listing Rule 5635(c)(4).

Unusual Whales

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, with earnings of 14 cents per share and sales of $156.413 million, both exceeding analyst expectations. The company reaffirmed its FY2026 sales guidance of $635-$660 million. Analysts revised their price targets, with Wedbush lowering it from $22 to $21, while Citizens raised it from $25 to $28. BioCryst shares fell 1% to $8.74 following the announcement.

benzinga_article

Citizens Financial

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

TD Cowen analyst Stacy Ku has reiterated a Buy rating on BioCryst (BCRX) stock, citing the strength of the Orladeyo franchise and the company's attractive valuation. Orladeyo shows strong demand with double-digit growth and stable prescriber additions, with a 2026 revenue guidance of $625–645 million. BioCryst trades at a discount, with potential for significant sales growth. Ku maintains a $30 price target, supported by positive physician feedback and long-term growth prospects. Needham also maintains a Buy rating with a $16 price target.

- TD Cowen analyst Stacy Ku maintains a bullish outlook on BCRX shares, assigning a buy rating due to Orladeyo's strong demand and attractive valuation.  
- Orladeyo shows double-digit year-over-year growth with stable increases in prescriber numbers, supporting revenue guidance of $625 million to $645 million for 2026.  
- Despite BioCryst’s significant discount relative to expected 2027 earnings, Orladeyo and navenibart are projected to peak at approximately $1 billion in HAE sales.

Tip Ranks

Toronto Dominion Bank

Supernus Pharma

Aurinia Pharma

Protara Therapeutic

BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target

BioCryst Pharma (NASDAQ:BCRX) reported Q1 2026 net revenue of $148.3 million, meeting expectations, with strong new patient prescriptions. Despite a manufacturing issue affecting the pediatric formulation of Orladeo, the company maintains its 2026 revenue guidance of $625-$645 million. The development of Nevenibart is progressing well, with the Phase 3 Alpha Orbit trial nearing completion. The acquisition of Astria Therapeutics is ahead of schedule, contributing to a 17% year-on-year revenue increase. BioCryst remains focused on expanding its market presence and addressing pediatric needs in HAE prophylaxis.

Astria Therapeutics

Full Transcript: BioCryst Pharma Q1 2026 Earnings Call

Earnings Watch

BioCryst Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 156.41 M